Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Ursodeoxycholic Acid. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN108546691A details a novel 7β-HSDH mutant using NADH for cost-effective ursodeoxycholic acid production with high purity and yield.
Novel patent CN119462811A offers high-yield ursodeoxycholic acid synthesis with reduced steps and enhanced safety for reliable pharmaceutical intermediate supply chains.
Patent CN115181150A details a green synthesis of UDCA from phytosterol derivatives, offering high yield and reduced chromium pollution for reliable API intermediate supply.
Patent CN109402212B reveals a novel fusion enzyme method for TUDCA production, offering significant cost reduction in bile acid manufacturing and reliable supply chain scalability.
Patent CN119119158B reveals a novel plant-derived synthesis route for ursodeoxycholic acid offering significant supply chain stability and cost reduction advantages.
Novel silylation technology for UDCA purification offers high selectivity and reduced solvent consumption for pharmaceutical intermediate manufacturing supply chains.
Patent CN102718829B reveals high-yield TUDCA synthesis avoiding ion-exchange columns ensuring cost reduction and supply reliability for global pharmaceutical intermediates
Patent CN113480589B details a novel DMAP salt method for UDCA purification ensuring high yield and purity for reliable pharmaceutical intermediate supply chains.
Patent CN114592027A reveals a novel two-step method for Tauroursodeoxycholic Acid production, offering significant cost reduction in API manufacturing and high-purity outcomes.
Patent CN114958699A reveals a novel dual-enzyme co-expression strategy for ursodeoxycholic acid, offering superior purity and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN118388570A reveals a novel enzymatic-chemical hybrid route for UDCA intermediates. Achieve superior selectivity and safety for pharmaceutical manufacturing.
Patent CN116103254B reveals stable enzyme mutants for UDCA. Offers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Novel synthesis of 3 beta-ursodesoxycholic acid via selective esterification and stereoselective reduction. High yield, mild conditions, cost-effective manufacturing solution.
Patent CN102660755B reveals electroreduction method for UDCA. Offers cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Patent CN113736842B reveals high-purity TUDCA production via multi-cell catalysis. Offers cost reduction in API manufacturing and enhanced supply chain reliability for global buyers.
Patent CN106701882A details a novel chemo-enzymatic route for UDCA production offering high purity and scalable manufacturing capabilities for global pharmaceutical supply chains.
Patent CN103319560A details a high-yield UDCA synthesis from CDCA using NBS oxidation and Luche reduction, offering cost reduction in API manufacturing and reliable pharmaceutical intermediates supply.
Novel borate catalysis method for TUDCA synthesis ensures high purity and reduced cost. Scalable process for pharmaceutical intermediates supply chain optimization and reliability.
Patent CN114940964B reveals efficient UDCA production. Reduced costs and high purity for pharmaceutical supply chains.
Patent CN115011661B reveals enzymatic synthesis for 3 beta-ursodeoxycholic acid. High purity, mild conditions, scalable supply chain solutions for pharma.